Background: The endogenous opioid system plays a significant role in alcohol dependence. The goal of the current study was to investigate regional brain mu-opioid receptor (MOR) and deltaopioid receptor (DOR) availability in recently abstinent alcohol-dependent and age-matched healthy control men and women with positron emission tomography (PET) imaging.
I
T IS GENERALLY accepted that the mesocorticolimbic system mediates the rewarding effects of most drugs of abuse including alcohol (Herz, 1998) . Within this key region of the brain, the reinforcing effects of alcohol are modulated in part by an increase in the neurotransmission of opioid peptides and dopamine (for review, see Oswald and Wand, 2004) . The endogenous opioid peptides (b-endorphin, enkephalins, and dynorphins) bind to different subtypes of the opioid receptor (OR). Specifically, b-endorphin binds with equal affinity to mu-opioid receptor (MOR) and delta-opioid receptor (DOR) subtypes. Enkephalins also bind to MOR and DOR subtypes but show a 20-fold greater affinity for DOR subtypes. b-endorphin and enkephalin opioid peptides increase dopamine neurotransmission within the nucleus accumbens via interactions with the MOR and DOR (Koob et al., 1998) .
There is strong evidence supporting an association between the endogenous opioid system and alcohol drinking and reward in humans and laboratory animals (Gianoulakis, 2004) . In laboratory animals, OR antagonists decrease alcohol consumption (Franck et al., 1998; Froehlich, 1995; Froehlich et al., 1991; June et al., 1999; Krishnan-Sarin et al., 1995a ,b, 1998 and block alcohol-induced activation of the dopamine system (Benjamin et al., 1993; Job et al., 2007) . MOR knockout mice self-administer alcohol at lower levels when compared to wild-type controls (Becker et al., 2002; Hall et al., 2001; Roberts et al., 2000) . In 2 related human laboratory studies (McCaul et al., 2000 (McCaul et al., , 2001 , naltrexone significantly attenuated alcohol-induced increases in liking and best effects, heart rate and diastolic blood pressure, and neuroendocrine responses. These findings have been replicated (Peterson et al., 2006) . Taken together, the above studies highlight the importance of the opioid system in the reward pathway for alcohol and provided support for the use of OR antagonists in the treatment for alcohol dependence. Indeed, meta-analyses of randomized clinical trials have demonstrated that the OR antagonist naltrexone has an overall small to moderate effect size in reducing drinking and relapse in alcohol-dependent subjects (Anton and Swift, 2003; Srisurapanont and Jarusuraisin, 2005) .
Given the evidence for a functional involvement of the endorphin and enkephalin systems in alcohol drinking and dependence, it is highly likely that the opioid system is altered in human alcoholics. Positron emission tomography (PET) is the only technique available for examining brain receptor characteristics in living human subjects. Three PET imaging studies available to date showed conflicting results on OR in alcohol-dependent men. In the first study (Bencherif et al., 2004) , MOR were lower in the right dorsal lateral prefrontal cortex, the right anterior frontal cortex, and right parietal cortex in 8 recently detoxified alcohol-dependent men when compared with 8 normal healthy men. The second study (Heinz et al., 2005) found an increase in MOR in the ventral striatum in 25 recently abstinent (1 to 3 weeks) alcohol-dependent men when compared with 10 healthy control men. A third PET study (Williams et al., 2009 ) examined OR in 11 alcoholdependent and 13 healthy control men using the nonselective OR ligand [ 11 C]diprenorphine, which binds to all 3 OR subtypes. Subjects were scanned while undergoing an outpatient detoxification with chlordiazepoxide after 2 to 4 weeks of self-reported alcohol abstinence. In this study, global and regional [ 11 C]diprenorphine volumes of distribution were higher in alcohol-dependent patients when compared with controls, although this effect was not statistically significant.
The current study therefore assessed binding characteristics of MOR and DOR with PET using [ 11 C]-carfentanil (CFN), a MOR ligand, and [ 11 C]-methylnaltrindole (MeNTL), a DOR ligand, in recently abstinent alcohol-dependent and agematched healthy control subjects. Alcohol-dependent subjects were admitted to the clinical research unit (CRU), completed medically supervised withdrawal, and completed PET scans on day 5, after withdrawal symptoms had subsided. Control subjects completed PET scans after an overnight stay on the CRU. Two types of analyses were utilized, volumes of interest (VOI) and statistical parametric mapping (SPM) analysis.
MATERIALS AND METHODS

Subjects
Current, heavy alcohol-dependent drinkers and healthy control subjects between 21 and 60 years of age were recruited via advertisement and provided informed consent, in the sober state, using an Institutional Review Board-approved informed consent document. Subjects were interviewed by a masters-level research assistant who utilized a battery of standardized diagnostic and psychological instruments. For inclusion in the study, alcohol-dependent subjects met DSM-IV criteria for alcohol dependence based on the Semi-Structured Assessment of the Genetics of Alcoholism (Bucholz et al., 1994) and were actively drinking at NIAAA-defined hazardous levels as determined by completion of a 90-day Time Line Follow Back (TLFB) (Sobell and Sobell, 1992) . Healthy control subjects did not drink above the NIAAA-recommended guidelines (<8 drinks ⁄ week for women and <15 drinks ⁄ week for men) and had never meet DSM-IV criteria for either alcohol abuse or alcohol dependence. Healthy control subjects were age-matched with alcohol-dependent participants. Alcohol-dependent and healthy control subjects were excluded from study participation based any on the following criteria: (i) if they met current or lifetime DSM-IV diagnostic criteria for any other Axis I disorder, including other drug abuse ⁄ dependence (except nicotine), (ii) if urine drug toxicology was positive at screening or hospital admission, (iii) if they had other ongoing health problems, or (iv) if their mother drank during pregnancy, subject was excluded from further study participation. Alcohol-dependent subjects were excluded if they reported alcohol-related seizures or the need for medication during previous detoxifications. Using these inclusion and exclusion criteria, a total of 25 alcohol-dependent subjects and 30 healthy control subjects completed the protocol. Basic demographic characteristics for alcohol-dependent and healthy control subjects are shown in Table 1 .
The Alcohol Dependence Scale (ADS) (Skinner and Allen, 1982 ) was administered to characterize alcohol use and associated problems. The Fagerstrom Nicotine Dependence Test (FNDT) was administered to determine nicotine dependence status in individuals who smoked cigarettes. Scores for each of these assessments are shown in Table 1 . The Family History Assessment Module (Rice et al., 1995) was completed to determine the number of first-and second-degree relatives with symptoms of alcohol and drug abuse or dependence. Subjects were classified as family history positive (FHP) if at least 3 diagnostic criteria for alcohol dependence were met by either parent (father or mother) or 3 or more other first-or seconddegree relatives. If mother drank during pregnancy, subject was excluded from further study participation. Subjects were classified as family history negative (FHN) if they reported (i) no first-degree relative who met alcohol dependence criteria and (ii) no or 1 seconddegree relative who met alcohol dependence criteria. Subjects were designated as family history undetermined (FHU) who did not meet criteria for FHP or FHN, had multiple relatives with drug problems but no alcohol problems, or could not provide sufficient information on alcoholism status of relatives.
Inpatient Procedures Following Admission to CRU
Healthy control subjects completed PET imaging following an overnight stay in the hospital or under an inpatient protocol. Alcohol-dependent subjects completed the study under an inpatient protocol that included hospital admission and medically supervised alcohol withdrawal prior to PET imaging on day 5 of supervised abstinence. Alcohol-dependent subjects remained on the CRU for subsequent naltrexone treatment (50 mg per day) and PET imaging to determine naltrexone blockade of mu and delta receptors. The methodology and results for [ 11 C]CFN binding potential (BP ND ) in the context of naltrexone treatment in 21 of 25 alcohol-dependent subjects were reported in a separate paper (Weerts et al., 2008) . The analysis of the basal scan data in the control subjects and comparison with basal scan data in the alcohol-dependent subjects are unique to the current article.
Following admission to the CRU and regularly throughout their hospital stay, subjects completed a second battery of psychological assessments, which included a Visual Analog Scale (VAS) of alcohol craving, Penn Craving Scale (Flannery et al., 1999) , the Obsessive Compulsive Drinking Scale (OCDS) (Anton et al., 1996) , Beck Depression Inventory (BDI-II) (Beck et al., 1996) , the Beck Anxiety Inventory (BAI) (Beck et al., 1988) , and the Brief Symptom Inventory (BSI) (Derogatis and Melisaratos, 1983) .
To monitor the severity of withdrawal symptoms, CRU nursing staff completed the Clinical Institute Withdrawal AssessmentAlcohol Revised (CIWA-Ar) (Sullivan et al., 1989) with alcoholdependent participants 3 times each day for the first 5 days. CIWA-Ar items were scored to reflect the time period since the last measurement. No subject required withdrawal medication based on CIWA scores, vital signs, and physician assessment.
During hospitalization and all study procedures, cigarette smoking was prohibited. Smokers who were nicotine dependent as determined by an FNDT score of 3 or higher received a new transdermal nicotine patch (21 mg nicotine) at the time of hospital admission, in the morning of each day while on the CRU and 3 hours prior to the PET scan. This standardized approach was used to limit the possible impact of nicotine withdrawal on the day of the scan. All subjects received a calorie-controlled breakfast 3 hours before the first scan. Before PET procedures and randomly during the hospital stay, urine toxicology screens and breath alcohol tests were conducted in all subjects to verify abstinence from alcohol and drugs.
PET Procedures
Subjects underwent 2 PET scans in a fixed order on the same day; the [ 11 C]MeNTL, a specific DOR antagonist (Lever et al., 1992; Madar et al., 1996) , and [ 11 C]CFN, a specific MOR agonist (Frost et al., 1985; Titeler et al., 1989) , scans were conducted at 8:30 and 10:45 am, respectively. A total of 25 alcohol-dependent subjects and 24 healthy control subjects completed [ Table 1 . Alcoholdependent subjects were about 44 years old, mostly men (n = 15) and Caucasian (n = 12), with 55% (n = 11) reporting a positive family history of alcoholism. Healthy controls were also about 44 years old, mostly men (n = 11) and Caucasian (n = 10), with 28% (n = 5) reporting a positive family history of alcoholism.
PET scans were acquired in 3D mode on a GE Advance PET scanner (GE Medical Systems, Milwaukee, WI). A thermoplastic mask was individually fitted to each subject's face for immobilization and positioning during imaging. A transmission scan of 10-minutes duration was obtained using rotating germanium-68 rods before the injection of the radiotracer. After intravenous bolus administration of the radiotracer, a set of 25 images with variable time period (6 · 30, 5 · 60, 5 · 120, 9 · 480 seconds) was acquired during a 90-minute period for each study. Table 2 shows the injected dose, specific activity, and mass for alcohol-dependent and control subjects. During [ 11 C]MeNTL scans, small amounts of arterial blood samples were collected every 5 seconds initially, and then, increasing intervals throughout the scan (e.g., 1, 2, 5, 10, and 15 minutes), counted for the radioactivity. Selected samples were analyzed with high performance liquid chromatography for metabolites (Hilton et al., 2000) . PET images were reconstructed using the back-projection algorithm with a ramp filter using the software provided by the manufacturer correcting for attenuation, scatter, and dead time (Kinahan and Rogers, 1989 ). The radioactivity was corrected for physical decay to the injection time. Each PET frame consisted of a 128 · 128 · 35 matrix with voxel size of 2 · 2 · 4.25 mm in a spatial resolution of 5.5 and 6.1 mm full width at half maximum (FWHM) in the radical and tangential directions, respectively, at 10 cm radius from the center of the field-of-view (Lewellen et al., 1996) . About 1 week before CRU admission, subjects underwent magnetic resonance imaging (MRI) to allow anatomical localization and alignment of PET imaging planes within subjects (Meltzer et al., 1990) .
VOI Analyses
VOI were limited in this study to the ventral striatum, cingulate cortex, caudate nucleus, putamen, insula, globus pallidus, thalamus, and amygdala. The VOI were manually defined on spoiled gradientrecalled echo MRI for putamen, caudate nucleus, and thalamus using a locally developed VOI-defining tool. The ventral striatum was defined as described previously (Baumann et al., 1999; Martinez et al., 2003; Oswald et al., 2005) . For the remaining VOI, a standard VOI template (Hammers et al., 2003; Mazziotta et al., 1995;  available at http://www.loni.ucla.edu) was spatially transferred to individual subjects' MRI, using the MRI-to-MRI spatial normalization parameters obtained with the SPM spatial normalization module Ashburner and Friston, 2004 ; available at http://www.fil.ion.ucl.ac.uk/spm), and edited to suit outlines of the structures given by the MRI. Those VOI were transferred to PET space according to the MRI-to-PET coregistration parameters obtained with the SPM2 coregistration module and applied to individual PET frames to obtain time-radioactivity curves of VOI.
Pharmacokinetic Modeling
The primary outcome variable of interest for MOR and DOR was BP ND (Innis et al., 2007) (Logan et al., 1996) was used, with occipital lobe as the reference region and setting the brain-to-blood clearance rate constant of the reference region (k 2 R ) at 0.104 per minute (Endres et al., 2003; Frost et al., 1990) . Estimates of BP ND using RTGA have been shown to be highly correlated with those obtained from the arterial input-based kinetic model (Endres et al., 2003) . The analyses for [ 11 C]MeNTL differed from that used for [ 11 C]CFN. First, we analyzed data using a 2-tissue compartmental model (TTCM). It was determined that, although TTCM fit the data well, there were occasional outliers (<10% of regions). We then examined data using the plasma reference graphical analysis (PRGA) (Logan et al., 1990 ) to obtain distribution volume (V T ); [ 
VOI Statistical Analyses
All statistical analyses were carried out using SAS version 9.2 (SAS Institute Inc., Cary, NC). Possible differences in regional binding of [ 11 C]CFN and [ 11 C]MeNTL between groups (alcohol-dependent and healthy control subjects) were determined using independent analyses of covariance (ANCOVAs) for each of the 8 brain volumes. We included both age and gender as covariates in the model because both have been shown to influence [ 11 C]CFN BP ND (Zubieta et al., 1999) . Smoking status was added as covariate in a secondary analysis, based on findings as indicated in the results. Independent ANCOVAs for each brain volume were performed over a model including the VOI as an independent variable because of nonhomogenous variance between VOI. The adaptive step-down Bonferroni adjustment (Hochberg and Benjamini, 1990) , which is based on the Bonferroni-Holm (Holm, 1979) MeNTL with family history of alcoholism, psychological problems (BDI, BAI, BSI scores), craving (OCDS, VAS, and Penn Craving Scale scores), recent drinking from the TLFB (drinks per episode, episodes per week, total drinks), and alcohol withdrawal severity (CIWA scores) were each analyzed as independent ANCOVAs. The adaptive step-down Bonferroni adjustment (Hochberg and Benjamini, 1990 ) was applied to correct for multiple comparisons (i.e., all 8 VOI), and the adjusted p-values (shown as Q) are reported.
SPM Analyses
SPM analyses were conducted to corroborate VOI findings and determine whether the regional increases in [ 11 C]CFN BP ND in alcohol-dependent subjects were more generalized and extended to other regions not examined in our VOI analysis. Functional volumes (voxel-by-voxel maps) of BP ND were spatially normalized to a standard brain using MRI-to-MRI spatial normalization and PET-to-MRI coregistration parameters using SPM5 modules and smoothed with a Gaussian filter of 12 mm FWHM. Parametric statistical models are assumed at each voxel, using the general linear model. Additional analysis was conducted controlling for current smoking status as a nuisance variable. To reduce chances of false positives, the search volume was limited to gray-matter voxels to eliminate whitematter clusters. Voxel-wise statistical tests were performed to examine the differences in BP ND between alcohol-dependent and healthy control subjects. A significance level of p < 0.05, family-wise error corrected, was employed for the group difference (t > 4.6).
RESULTS
VOI Analysis of Covariance of Alcohol-Dependent Versus Healthy Control Subjects
When controlling for age and gender, alcohol-dependent subjects had higher [ 11 C]CFN BP ND than healthy control subjects across all VOI. This effect was highly significant across regions [amygdala (p and Q = 0.004), cingulate (p and Q = 0.002), insula, ventral striatum, caudate, globus pallidus, putamen, and thalamus (all p and Q < 0.001)]. In contrast, [ 11 C]MeNTL BP ND did not differ between alcoholdependent and healthy controls subjects in any region. The mean (±SD) V T of cerebellum was not different between alcohol-dependent subjects (7.75 ± 1.57 ml ⁄ ml) and healthy control subjects (8.0 ± 1.53 ml ⁄ ml; t = 0.47; df = 36; p = 0.638).
ANCOVA also confirmed an overall effect for gender on [ The addition of smoking status as a nuisance variable in the contrast analysis of alcohol-dependent and healthy control subjects did not change this result. Specifically, group differences were identified as 2 large, symmetrical volumes of 218 ml (left) and 222 ml (right), which peaked at thalamus (Fig. 4) . The x, y, z coordinates were 20, )12, 4 (Peak T = 7.5) for left and )22, 12, 6 (Peak T = 7.49) for right volumes, respectively (Fig. 4 ). There were no differences between alcohol-dependent and healthy control subjects in [ 11 C]CNF BP ND in para-sagittal areas.
In contrast, consistent with the VOI analysis, SPM analysis did not reveal any significant differences in [ 11 C]MeNTL BP ND between alcohol-dependent and healthy control subjects.
Secondary Analyses of Impact of Severity of Alcohol Dependence and Drinking History
As shown in Table 1 , alcohol-dependent subjects scored significantly higher than healthy controls on measures of alcohol dependence severity (ADS score) and recent alcohol drinking recorded on the TLFB (drinks per drinking day, drinks per week, total drinks last 90 days; all p < 0.0001, ttest). There was a significant positive association of recent drinking and [ C]MeNTL BP ND were also not significantly associated with ADS score, age first met criteria for alcohol dependence, or years of heavy drinking in alcohol-dependent subjects.
During the inpatient protocol, moderate alcohol withdrawal symptoms, as determined by peak scores on the CIWA-AR across days 1 to 5 postadmission, were observed and ranged from 1 to 12 (mean peak score = 5 ± 2.6 SD) for alcoholdependent subjects. Alcohol withdrawal symptoms had subsided by day 5 (mean CIWA score on day 5 = 0.44 + 1.1 SD) when PET scans were conducted. CIWA scores on the day of the PET scans did not differ between alcohol-dependent and healthy control groups (Table 1) . When controlling for smoking status, age, and gender, neither peak CIWA across days 1 to 5 nor prescan CIWA scores predicted [ 
Secondary Analyses of Family History of Alcoholism
Because family history is a known risk factor for alcoholism, we examined whether family history predicted [ 
control) for each volumes of interest (VOI). Q-values
show adjusted p-values using the step-down Bonferroni-Holm adjustment (Hochberg and Benjamini, 1990) to correct for multiple comparisons. Significant VOI with adjusted p < 0.05 are highlighted in bold type.
(n = 5) did not differ from FHN subjects (n = 11) in any of the VOI (p > 0.08, Q > 0.3).
Secondary Analyses on Impact of Psychological Problems and Alcohol Craving
As shown in Table 1 , alcohol-dependent subjects reported significantly more symptoms of anxiety (BAI), depression (BDI), and psychological problems (BSI) than healthy control subjects (all p < 0.0001, t-test). ANCOVA of these data indicated there was not a direct relationship between anxiety, depression, and global measures of psychological problems as measured by the BAI, BDI-II and BSI, and [ Alcohol-dependent subjects reported higher alcohol craving in the Penn Craving Scale, VAS, and OCDS than healthy control subjects (Table 1, 
DISCUSSION
There were 5 primary findings of the current study. First, 5-day abstinent alcohol-dependent men and women had higher [ 11 C]CFN BP ND when compared with age-matched healthy control men and women in brain regions, which included the ventral striatum, amygdala, caudate, globus pallidus, insula, putamen, and thalamus. This observation remained after adjusting for age, gender, and smoking status. The SPM analysis corroborated this finding and indicated that the alcohol effect is even more global than the VOI analyses suggest. Heinz and colleagues (2005) . In addition, alcohol-dependent subjects had significantly higher [ 11 C]CFN BP ND in amygdala, caudate, globus pallidus, insula, putamen, and thalamus. Our finding that the increase in [ 11 C]CFN BP ND may be more extensive is consistent with the reported trend toward an increase in regional and global [ 11 C]diprenorphine volumes of distribution in alcohol-dependent patients (n = 11) when compared with controls (n = 13), although this effect was not statistically significant (Williams et al., 2009) . The authors note the study may have been under-powered and that there was substantial variability possibly related to [ 11 C]diprenorphine binding to all 3 subunits (l, d, and j) of the OR.
The methodology for the current study differs from these previous studies in the following important ways. First, we enrolled both male and female alcohol-dependent and agematched healthy subjects and used stringent psychological assessment procedures to ensure no current drug use, no other drug use disorders, and no other current or lifetime Axis I psychiatric disorders. Age, gender, other drug use disorders, and psychiatric problems are important confounders that are known to influence the endogenous opioid system. Second, all subjects were housed in the same inpatient research unit where diet was controlled, smoking was prohibited, and urine toxicology screens verified no other drug use prior to imaging. For alcohol-dependent subjects, all scans were conducted under an inpatient detoxification protocol where alcohol abstinence was supervised, and the timing of onset of alcohol abstinence and imaging was fixed. Alcohol-dependent subjects were enrolled in the study while actively drinking, and abstinence was initiated at the time of inpatient admission. Third, both MOR and DOR were examined via PET scans (Hochberg and Benjamini, 1990) to correct for multiple comparisons. Significant VOI with adjusted p < 0.05 are highlighted in bold type.
with carbon 11-labeled [ 11 C]CFN, a MOR-selective radioligand, and [ 11 C]MeNTL, a DOR-selective radioligand, in the same subjects under conditions of validated alcohol abstinence and on the same day (day 5) of abstinence. Change in the endogenous opioid system following alcohol abstinence is a dynamic process, and these changes are likely greatest during early abstinence. Thus, fixing the time of scanning to a specific day during early abstinence minimizes the variance in the data introduced when the scanning time is allowed to vary by days or weeks. Fourth, withdrawal medications (e.g., benzodiazepines), which can alter OR function (Cox and Collins, 2001) , were not used. Fifth, we examined 8 brain VOI in mesolimbic opioid-rich regions, including the ventral striatum and the amygdala, which have been associated with alcohol reinforcement, dependence, and craving. Last, as many alcohol-dependent subjects were also smokers, we specifically recruited healthy smokers without heavy drinking or alcohol problems to balance and control for smoking. This point is particularly relevant as approximately 80% of alcoholdependent subjects report regular tobacco use (Batel et al., 1995; DiFranza and Guerrera, 1990 ) and smoke at high rates (Dawson, 2000) , when compared with social drinkers. Comparison subjects used in previous PET studies did not include smokers without alcohol problems. Thus, the current study used a rigorous level of control over other drug use and psychiatric disorders, the duration of alcohol abstinence and cigarette smoking. It is likely that significance was achieved in the current study because of the larger sample size and control over these potential confounding effects.
Previous studies in healthy human volunteers using [C 11 ]-MeNTL PET imaging have shown that DOR rich areas include neocortical regions (insular, parietal, frontal, cingulate, and occipital), caudate nucleus, putamen, and amygdala (Madar et al., 1996) . In addition, [ 11 C]MeNTL PET imaging has been utilized successfully to examine group differences in other disease states such as epilepsy (Madar et al., 1997) and carcinoma (Madar et al., 2007) . This is the first study to compare DOR availability in recently abstinent alcohol-dependent and healthy control human subjects. Interestingly, we found a positive association of recent drinking (average drinks per drinking day) with [ 11 C]MeNTL BP ND in the caudate for alcohol-dependent subjects. These data suggest that the delta receptor may be sensitive to recent alcohol drinking history. These data provide evidence of some role of the DOR in alcoholism, particularly when taken together with our previous report showing that the clinical dose of naltrexone (50 mg) produced only partial inhibition (21%) and substantial intersubject variability of [ 11 C]MeNTL binding in alcohol-dependent subjects (Weerts et al., 2008) . Because this same dose of naltrexone produces near-complete inhibition (95%) of [ 11 C]CFN binding, it seems likely that the magnitude of DOR blockade by naltrexone may contribute to the variability of naltrexone treatment outcomes and may be influenced by baseline differences in DOR availability prior to the treatment. The current study did not reveal significant [ 11 C]MeNTL BP ND differences between groups. These data are in contrast to preclinical studies in alcohol-preferring and alcohol-nonpreferring rodent strains, which have shown increases and decreases in DOR density in mesolimbic regions (de Waele et al., 1995; Marinelli et al., 2000; McBride et al., 1998; Soini et al., 1998) . Because intersubject variations (measured as coefficient of variation) were similar between The intersection of the blue lines targets the peak in the thalamus. Smoking status was added a nuisance variable in the contrast analysis of alcohol-dependent and healthy control subjects. Colored legend depicts peak t-values ranging from 0 (red) to 7.5 (yellow ⁄ white). Significant differences between alcoholdependent and healthy control subjects are shown in yellow (t-values >4.6, p < 0.05 family-wise error [FWE] in alcohol-dependent subjects compared with healthy controls could be a consequence of (i) alcohol withdrawal, (ii) long-term hazardous alcohol drinking ⁄ dependence, (iii) inherited differences in the opioid system, and ⁄ or (iv) acquired differences owing to environmental factors (e.g., childhood adversity, chronic stress) that might alter [
There is support for some of these possibilities. Studies in rodents have reported increased MOR binding in limbic areas, including the nucleus accumbens, after extended alcohol consumption (5 weeks) (Cowen et al., 1998 (Cowen et al., , 1999 Djouma and Lawrence, 2002) and during alcohol withdrawal (1 to 10 days) (Djouma and Lawrence, 2002) . Studies examining genetic variations in opioid activity in rodent lines have also demonstrated greater MOR density in limbic structures, such as the nucleus accumbens and amygdala in the alcoholpreferring lines, when compared with the nonpreferring lines (de Waele et al., 1995; Marinelli et al., 2000; McBride et al., 1998) , although not in all studies (Fadda et al., 1999) . Although we did not find a direct relationship between [ 11 C]CFN BP ND and measures of anxiety, depression, and psychological problems, alcohol-dependent subjects reported significantly greater symptoms for all of these measures than healthy control subjects, even after exclusion of people with a history of other Axis I disorders.
In the current study, detailed family histories were obtained from the participants, and subjects were classified according to family histories of alcoholism. The increase in [ Likewise, previously we reported there were no significant differences in amphetamine-induced mesolimbic dopamine release, subjective responses, or stress hormone measures as a function of family history of alcoholism (Munro et al., 2006) . It seems unlikely that the observed elevation in [ 11 C]CFN BP ND can be attributed to acute abstinence alone. We did not observe a relationship between BP ND and alcohol withdrawal severity as measured by the CIWA-Ar in the current study. Our selection of alcohol-dependent subjects with relatively mild alcohol withdrawal symptoms may have diminished our ability to observe such an effect. In the study by Heinz and colleagues (2005) , increased MOR availability in the ventral striatum was observed after 1 to 3 weeks of alcohol abstinence and remained elevated and stable 5 weeks later when [ 11 C]CFN PET scans were repeated in a subset of alcohol-dependent subjects. Similarly, [ 11 C]diprenorphine volumes of distribution were stable when examined at 2 weeks and again 2 months after alcohol abstinence (Williams et al., 2009 ).
Neither our study nor the study by Heinz and colleagues (2005) within the alcoholdependent subjects may be compromised by the homogeneity and chronicity of the sample (i.e., all were long-term heavy drinkers). Increases in MOR binding were observed in rodents after only 5 weeks of alcohol consumption. If chronic alcohol drinking produced an up-regulation of MOR, it likely occurred earlier in the progression from regular drinking to dependence and could not be detected in our relatively homogonous sample of long-term alcohol-dependent drinkers.
We found an inverse relationship between craving scores on the VAS and [ 11 C]CFN BP ND in several brain regions including the ventral striatum, thalamus, and cingulate. Interestingly, alcohol-dependent subjects show greater activation of these same brain regions in response to alcohol cues (a sip of alcohol and pictures of alcoholic beverages) when compared with control cues in functional MRI studies (George et al., 2001; Myrick et al., 2004) ; activation in cingulate and nucleus accumbens was correlated with higher craving in alcoholic and not social drinkers (Myrick et al., 2004) . The inverse correlation with craving in the current study was unexpected, as alcohol-dependent subjects reported higher craving and had higher [ (Heinz et al., 2005; Williams et al., 2009) . The OCDS scores obtained on the day of the PET scans in the current study were comparable to those in the Heinz and colleagues (2005) study. An inverse relationship between craving and dopamine D2 receptor ligand [ 18 F]desmethoxyfallypride BP ND in the ventral striatum in alcohol-dependent subjects has been reported (Heinz et al., 2004) . Although it appears that D2 and MOR receptors behave oppositely in alcohol dependence, a similar inverse relationship with craving may occur. For example, if opioid peptides are reduced by chronic alcohol drinking leading to the up-regulation of MOR, then greater up-regulation of MOR may result in greater opioid transmission and less craving compared with individuals with less up-regulation. In the case of alcohol-related reductions in endogenous opioid release, the up-regulation of receptors would have to be proportionally more than the reduction in opioids for there to be net increase in opioid neurotransmission. This would bring craving closer to that in normal individuals, but not normalize it completely. This mechanism is speculative and further studies are needed to determine whether this hypothesis is supported.
There were some study limitations that may limit generalization of these findings. We selected alcohol-dependent subjects without prior histories of serious withdrawal symptoms and excluded subjects who had previously required benzodiazepine treatment for withdrawal symptoms. Thus, subjects who experienced more severe forms of alcohol withdrawal were excluded from participation in the study. Yet, despite this conservative selection of subjects with modest withdrawal symptoms, differences in [ 11 C]CFN BP ND between alcoholdependent subjects and controls were highly significant across multiple brain volumes. An additional consideration is subjects were long-term alcohol-dependent drinkers (i.e., an average of 15 years of alcohol-dependent drinking). Thus, similar long-term exposure to alcohol for this homogenous sample may have reduced the ability to show relationships between [ 11 C]CFN BP ND and behavior ⁄ clinical measures. Additional studies in subjects with a wider range of drinking levels and with and without diagnosis of alcohol use disorders are needed to better understand the transitions in the opioid system as alcohol consumption progresses from social drinking to heavy drinking and then to alcohol dependence.
In summary, our observations that [ 
